Adipocyte-derived kynurenine stimulates malignant transformation of mammary epithelial cells through the aryl hydrocarbon receptor.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
10 2023
Historique:
received: 15 06 2023
revised: 17 08 2023
accepted: 21 08 2023
medline: 23 10 2023
pubmed: 26 8 2023
entrez: 25 8 2023
Statut: ppublish

Résumé

Anti-hormone therapies are not efficacious for reducing the incidence of triple negative breast cancer (TNBC), which lacks both estrogen and progesterone receptors. While the etiology of this aggressive breast cancer subtype is unclear, visceral obesity is a strong risk factor for both pre- and post-menopausal cases. The mechanism by which excessive deposition of visceral adipose tissue (VAT) promotes the malignant transformation of hormone receptor-negative mammary epithelial cells is currently unknown. We developed a novel in vitro system of malignant transformation in which non-tumorigenic human breast epithelial cells (MCF-10A) grow in soft agar when cultured with factors released from VAT. These cells, which acquire the capacity for 3D growth, show elevated aryl hydrocarbon receptor (AhR) protein and AhR target genes, suggesting that AhR activity may drive malignant transformation by VAT. AhR is a ligand-dependent transcription factor that generates biological responses to exogenous carcinogens and to the endogenous tryptophan pathway metabolite, kynurenine. The serum kynurenine to tryptophan ratio has been shown to be elevated in patients with obesity. Herein, we demonstrate that AhR inhibitors or knockdown of AhR in MCF-10A cells prevents VAT-induced malignant transformation. Specifically, VAT-induced transformation is inhibited by Kyn-101, an inhibitor for the endogenous ligand binding site of AhR. Mass spectrometry analysis demonstrates that adipocytes metabolize tryptophan and release kynurenine, which is taken up by MCF-10A cells and activates the AhR to induce CYP1B1 and promote malignant transformation. This novel hormone receptor-independent mechanism of malignant transformation suggests targeting AhR for TNBC prevention in the context of visceral adiposity.

Identifiants

pubmed: 37625554
pii: S0006-2952(23)00354-4
doi: 10.1016/j.bcp.2023.115763
pmc: PMC10587895
mid: NIHMS1930391
pii:
doi:

Substances chimiques

Hormones 0
Kynurenine 343-65-7
Ligands 0
Receptors, Aryl Hydrocarbon 0
Tryptophan 8DUH1N11BX
AHR protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115763

Subventions

Organisme : NCI NIH HHS
ID : R01 CA270136
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030695
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007255
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
J Vis Exp. 2014 Oct 27;(92):e51998
pubmed: 25408172
Pharmaceuticals (Basel). 2023 Feb 25;16(3):
pubmed: 36986451
J Hazard Mater. 2020 Nov 5;398:122869
pubmed: 33027880
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613
pubmed: 30733286
Annu Rev Immunol. 2014;32:403-32
pubmed: 24655296
Adipocyte. 2018;7(2):113-120
pubmed: 29561195
BMC Cancer. 2015 Dec 29;15:1026
pubmed: 26715507
Oncotarget. 2016 Oct 4;7(40):64854-64877
pubmed: 27588494
Am J Pathol. 2009 Sep;175(3):1255-69
pubmed: 19700761
J Cell Biochem. 2008 May 15;104(2):402-17
pubmed: 18059014
Anal Chem. 2010 Dec 1;82(23):9818-26
pubmed: 21049934
Mutat Res. 1999 Mar 8;424(1-2):237-47
pubmed: 10064864
Br J Cancer. 2009 Feb 24;100(4):578-82
pubmed: 19223908
Pharmaceuticals (Basel). 2021 Jun 23;14(7):
pubmed: 34201791
Cancer Res. 2015 Nov 1;75(21):4651-64
pubmed: 26363006
Biochem Pharmacol. 2000 Jan 1;59(1):65-85
pubmed: 10605936
Front Pharmacol. 2022 Dec 15;13:1095289
pubmed: 36588678
Front Immunol. 2020 Apr 15;11:557
pubmed: 32351500
Toxicol Sci. 2010 Oct;117(2):393-403
pubmed: 20634293
Front Endocrinol (Lausanne). 2016 Jul 06;7:84
pubmed: 27458427
PLoS One. 2016 Mar 16;11(3):e0151598
pubmed: 26981862
Curr Cancer Drug Targets. 2011 Jun;11(5):654-69
pubmed: 21486221
Int J Mol Sci. 2022 Aug 26;23(17):
pubmed: 36077068
Cell Prolif. 2016 Oct;49(5):554-60
pubmed: 27523394
Geroscience. 2023 Jun;45(3):1889-1898
pubmed: 36856946
Environ Res. 2020 Aug;187:109346
pubmed: 32445942
J Cancer Ther. 2013 Sep;4(7):1177-1186
pubmed: 25068070
J Biol Chem. 2004 Jun 4;279(23):23847-50
pubmed: 15028720
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396563
Clin Chim Acta. 2010 Mar;411(5-6):368-74
pubmed: 19995559
Mol Pharmacol. 2012 Jan;81(1):3-11
pubmed: 21967751
Arch Toxicol. 2018 Jan;92(1):541-551
pubmed: 28593498
Nat Commun. 2020 Aug 11;11(1):4011
pubmed: 32782249
Cancer Causes Control. 2021 Oct;32(10):1129-1148
pubmed: 34292440
Biol Chem. 2006 Sep;387(9):1175-87
pubmed: 16972784
Pestic Biochem Physiol. 2015 May;120:5-13
pubmed: 25987214
BMC Genomics. 2014 Oct 08;15:880
pubmed: 25297811
J Mol Med (Berl). 2022 Feb;100(2):215-243
pubmed: 34800164
Environ Res. 2018 Jan;160:152-182
pubmed: 28987728
Breast Cancer Res Treat. 2010 Oct;123(3):641-9
pubmed: 20711809
Breast Cancer Res. 2019 Aug 20;21(1):96
pubmed: 31429809
Biochem Pharmacol. 2016 Apr 15;106:94-103
pubmed: 26944194
Oncogene. 2017 Nov 30;36(48):6668-6679
pubmed: 28783178
Kaohsiung J Med Sci. 2012 Jul;28(7 Suppl):S22-7
pubmed: 22871597
Obesity (Silver Spring). 2014 Jan;22(1):195-201
pubmed: 23625535
Mol Pharmacol. 2016 Nov;90(5):674-688
pubmed: 27573671
Toxicol Sci. 2010 May;115(1):89-97
pubmed: 20106948
Mol Pharmacol. 2006 Jun;69(6):1871-8
pubmed: 16540597
Eur J Med Chem. 2020 Jan 1;185:111842
pubmed: 31727470
Obesity (Silver Spring). 2015 Oct;23(10):2066-74
pubmed: 26347385
Am J Epidemiol. 2000 Sep 15;152(6):514-27
pubmed: 10997541
J Exp Med. 1956 Feb 1;103(2):273-83
pubmed: 13286432
Int J Mol Sci. 2020 Jul 24;21(15):
pubmed: 32722276
Methods Mol Biol. 2019;1862:37-52
pubmed: 30315458
Metabolites. 2022 May 29;12(6):
pubmed: 35736425
J Steroid Biochem Mol Biol. 2015 Mar;147:24-30
pubmed: 25448748
Bio Protoc. 2016 Jul 5;6(13):
pubmed: 28573159
Sci Rep. 2022 Oct 5;12(1):16625
pubmed: 36198709
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
Circ Res. 2001 Sep 28;89(7):573-82
pubmed: 11577022
Br J Cancer. 2017 Apr 25;116(9):1229-1233
pubmed: 28350789
Bioinformatics. 2012 May 1;28(9):1294-6
pubmed: 22419781
Nat Commun. 2022 Jun 17;13(1):3489
pubmed: 35715443

Auteurs

Jonathan D Diedrich (JD)

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 USA.

Romina Gonzalez-Pons (R)

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 USA.

Hyllana C D Medeiros (HCD)

Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824 USA.

Elliot Ensink (E)

Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824 USA.

Karen T Liby (KT)

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 USA.

Elizabeth A Wellberg (EA)

Department of Pathology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Harold Hamm Diabetes Center, Oklahoma City, OK, USA.

Sophia Y Lunt (SY)

Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824 USA; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI 48824 USA.

Jamie J Bernard (JJ)

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 USA; Department of Medicine, Michigan State University, East Lansing, MI 48824 USA. Electronic address: jbernard@msu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH